Deals, Mergers and Acquisitions, and Licensing - Pharmaceutical Executive

ADVERTISEMENT

Deals
Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making

GSK to Work with Valeant on Epilepsy Drug

September 4, 2008

After a year of layoffs and restructuring, Valeant Pharma scores big with a collaboration deal worth up to $670 million.

Place Your Bets

September 1, 2008

The industry is a-changing. Here are eight seminal events that describe how.

Genentech Launches Employee Retention Program

August 20, 2008

Tacked on to Genentech's press statement about its rejection of Roche's offer, the biotech firm announced the formation of a program to address employee concerns.

BMS Bids on ImClone

August 6, 2008

Whether or not BMS's $4.5 billion offer for ImClone is fair is up in the air, but either way BMS stands to gain chunk of change if its bid is approved.

Roche Makes $44B Offer for Control of Genentech

July 23, 2008

After years of owning a majority share in Genentech, Roche makes a play to buy out the rest of the biotech firm.

Heparin Maker Acquired by German Firm

July 10, 2008

Fresenius snagged injectible manufacturer APP Pharmaceuticals in a $3.7 billion cash deal. Along with entry into the US market, Fresenius also gets access to one of the largest suppliers of heparin.

Merck Signs $100M Development Deal with Ranbaxy

May 14, 2008

In a win-win situation for both companies, Merck gets access to one of the hottest generics firms in the world while Ranbaxy gets a chance to hang with the big boys.

GSK Snags Sirtris for $720M

April 30, 2008

Small biotech company is creating a buzz with a diabetes drug that incorporates a component found in red wine. Pharm Exec talks to Sirtris CEO Christoph Westphal about the merger and the battle against diseases of aging.

Takeda Picks Up Millennium

April 16, 2008

Japanese drugmaker buys the cancer-specialist biotech for a whopping $8.8 billion.

ADVERTISEMENT

Click here